Affinity Asset Advisors Reports 6.4% Stake in NextCure, Inc. (NXTC)

Affinity Asset Advisors, LLC, along with Michael Cho, filed a Schedule 13G/A on August 13, 2026, reporting a 6.4% ownership stake in NextCure, Inc. (NXTC). The reporting persons disclosed beneficial ownership of 274,073 shares of common stock as of June 30, 2026. This position includes 232,113 shares issuable upon the exercise of warrants, subject to a 9.99% beneficial ownership limitation. The shares are directly held by Affinity Healthcare Fund, LP, with Affinity Asset Advisors acting as the investment manager and Michael Cho as the managing member. The filing marks an increase from a previously reported 0% ownership, indicating a new significant position in the clinical-stage biopharmaceutical company. The reporting persons have sole voting and dispositive power over the reported shares. The calculation of the 6.4% ownership is based on 4,301,064 shares outstanding, which accounts for both the issuer's outstanding common stock and the shares issuable upon exercise of the warrants held by the reporting persons.